Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
OS Therapies Inc
OSTX
Healthcare
Biotechnology
OS Therapies Incorporated is a clinical-stage biopharmaceutical company. The Company is focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. It built a pipeline of product candidates targeting multiple indications for solid cancers. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. OST-HER2 is an off-the...
-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH sensitive silicone linkers (SiLinkers). The payloads can include antibodies, chemotherapeutics, cytotoxins and potentially mRNA treatments directly into and in the vicinity of solid tumors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NYSEAM:OSTX)
New Post
View:
Posts & Comments
Threaded Posts
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 13, 2024 8:09am
New Press Release - OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
First therapeutic candidate targets Breast Cancer, Lung Cancer and Gastric CancerSecond therapeutic candidate targets platinum-resistant Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 11, 2024 8:17am
New Press Release - OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancerStrong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancerStrong safety profile for FRA-H with no loss of bodyweight as compared with control in animal...
read article.
Promino Nutritional Sciences Inc. Provides Shareholder Progress Report
posted Dec 14, 2024 9:00am by
Promino Nutritional Sciences Inc.
-
|
Promino Nutritional Science's rejuvenate muscle activator, delivers the equivalent of 40 grams of whey protein isolate for just 3.6 grams of the company’s product. That was just one of the highlights in the company’s update to investors covering a transformational period for the company as new management resurrects sales with an eye on the RTD market in 2025 ...read more
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 05, 2024 8:22am
New Press Release - OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced its participation in the H.C. Wainright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024...
read article.
(10)
•••
Mathew177
X
Post by
Mathew177
on Sep 03, 2024 9:06am
Investors Beware: The Fed, Trump, and the Volatility
Investors Beware: The Fed, Trump, and the Volatility That Could Rock Your Portfolio (NYSE-A: OSTX) https://10xalerts.com/investors-beware-the-fed-trump-and-the-volatility-that-could-rock-your
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Aug 29, 2024 7:53am
New Press Release - OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
OS Therapies Incorporated (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred...
read article.
(10)
•••
Mathew177
X
Post by
Mathew177
on Aug 22, 2024 12:48pm
OS Therapies Pioneers Hope for Osteosarcoma Patients
OS Therapies Pioneers Hope for Osteosarcoma Patients (NYSE-A: OSTX) https://10xalerts.com/os-therapies-pioneers-hope-for-osteosarcoma-patients/
(10)
•••
Mathew177
X
Post by
Mathew177
on Aug 21, 2024 10:30am
The Future of Medicine: Key Biotech Stocks to Watch
The Future of Medicine: Key Biotech Stocks to Watch ($OSTX , $CRBP , $PBYI , $ATNM ) https://www.openpr.com/news/3629390/the-future-of-medicine-key-biotech-stocks
...more
(8)
•••
Brice978
X
Post by
Brice978
on Aug 16, 2024 11:53am
Investment Opportunities in a Shifting Market (NYSE-A: OSTX)
Investment Opportunities in a Shifting Market: Rate Cuts and One Stock Pick (NYSE-A: OSTX) https://10xalerts.com/investment-opportunities-in-a-shifting-market-rate-cuts-and-one-stock-pick/
(6)
•••
ElliotGH
X
Post by
ElliotGH
on Aug 15, 2024 11:27am
A Potential Game-Changer for Osteosarcoma $OSTX
OSTX's OST-HER2: A Potential Game-Changer for Osteosarcoma (NYSE-A: OSTX) https://10xalerts.com/ostxs-ost-her2-a-potential-game-changer-for-osteosarcoma-nyse-a
...more
(10)
•••
Mathew177
X
Post by
Mathew177
on Aug 14, 2024 10:11am
OS Therapies Leading the Way to Breakthroughs in Cancer
OS Therapies Leading the Way to Breakthroughs in Cancer Treatment (NYSE-A: OSTX) https://10xalerts.com/os-therapies-leading-the-way-to-breakthroughs-in-cancer
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.